Recent developments of interest in cardiovascular medicine
The SGLT2 diabetes drug dapagliflozin (Farxiga) significantly reduced cardiovascular death and worsening of heart failure with reduced ejection fraction in topline results announced from the DAPA-HF trial among patients with and without type 2 diabetes. AstraZeneca called it a clinically meaningful effect.